Tilray | TRLY - Operating Expenses


Tilray reported $237.52M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Acasti Pharma USD 64.89M 2.07M Dec/2025
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
Alaunos Therapeutics USD 1.01M 175K Mar/2026
Aurora Cannabis CAD 48.04M 81.94M Mar/2026
Avita Medical AUD 28.02M 1.55M Dec/2025
Canopy Growth CAD 98.72M 11.51M Mar/2026
Cronos Group USD 46.66M 4.93M Mar/2026
Dianthus Therapeutics USD 47M 22.83M Mar/2026
Divis Laboratories Ltd INR 20.17B 1.85B Mar/2026
Ionis Pharmaceuticals USD 364M 54M Mar/2026
IQVIA Holdings USD 6.22B 4.53B Mar/2026
Knight Therapeutics CAD 126.9M 8.29M Dec/2025
Moderna USD 1.78B 242M Mar/2026
Organigram Holdings CAD 69.59M 14.08M Mar/2026
Organon & Co USD 903M 387M Mar/2026
Revvity USD 628.34M 2.12M Mar/2026
Tectonic Therapeutic USD 27.3M 5.78M Mar/2026
Tilray USD 237.52M 17.34M Sep/2025
Viatris USD 3.54B 323.9M Mar/2026
Xeris Pharmaceuticals USD 75.21M 6.18M Mar/2026
Zealand Pharma A/S 775.97M 265.08M Dec/2025